Vaccines are effective in preventing COVID-19-related emergency
department and urgent care visits for both children and adolescents
CDC study provides first real-world information on vaccine effectiveness
in 5- to 11-year-olds

Date:
March 1, 2022
Source:
Regenstrief Institute
Summary:
A new study shows that two doses of an mRNA vaccine provide
protection against COVID-19 associated emergency department and
urgent care visits among children ages 5 to 11. The study also
finds that two doses of an mRNA vaccine provide protection against
COVID-19 associated emergency department and urgent care visits
as well as very high protection against hospitalization among
adolescents aged 12 to 17.



FULL STORY ========================================================================== Using data from 10 states, a study from the U.S. Centers for Disease
Control and Prevention (CDC) is one of the first real-world studies
to show that two doses of an mRNA vaccine provide protection against
COVID-19 associated emergency department and urgent care visits among
children ages 5 to 11.


==========================================================================
The study also found that two doses of an mRNA vaccine provide protection against COVID-19 associated emergency department and urgent care visits
as well as very high protection against hospitalization among adolescents
aged 12 to 17.

"A positive pattern, similar to what we have reported in adults
is emerging," said study co-author Shaun Grannis, M.D., M.S., vice
president for data and analytics at Regenstrief Institute and professor
of family medicine at Indiana University School of Medicine. "Prevention
of emergency department and urgent care visits shows that the vaccines
are thwarting moderate COVID-19 in both children and adolescents;
prevention of hospitalizations in 12- to-17-year-olds indicates vaccine effectiveness against more serious disease in this age group, which we
hope to also see in 5-to-11-year-olds when there is sufficient data.

"We now have compelling evidence that vaccines and, for 16- and
17-year-olds, boosters, provide important protection for both children
and adolescents - - data-driven information that parents should take into consideration when making decisions for their family," said Dr. Grannis.

The study was conducted by the CDC's VISION Network which includes, in
addition to the Regenstrief Institute (Indiana), Baylor Scott & White
Health (Texas), Columbia University Irving Medical Center (New York), HealthPartners (Minnesota and Wisconsin), Intermountain Healthcare (Utah), Kaiser Permanente Northern California (California), Kaiser Permanente
Northwest (Oregon and Washington) and University of Colorado (Colorado).

"Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination
in Preventing COVID-19-associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Non-Immunocompromised Children
and Adolescents Aged 5-17 Years -- VISION Network, Ten States, April 2021-January 2022" is published in the CDC's Morbidity and Mortality
Weekly Report.

Regenstrief Institute authors of the study, in addition to Dr. Grannis,
are William F. Fadel, PhD and Brian E. Dixon, PhD, MPA, Regenstrief and
IU Richard M. Fairbanks School of Public Health; Nimish Ramesh Valvi,
DrPH, MBBS, a Regenstrief fellow; and Peter J. Embi, M.D., M.S., former Regenstrief president, and a current affiliate scientist.

All authors on this paper are Nicola P. Klein, M.D., Kaiser Permanente
Vaccine Study Center, Kaiser Permanente Northern California Division
of Research; Melissa Stockwell, M.D., Division of Child and Adolescent
Health, Department of Pediatrics, Columbia University Vagelos College
of Physicians and Surgeons, Department of Population and Family Health, Columbia University Mailman School of Public Health, New York-Presbyterian Hospital; Maria Demarco, PhD, Westat; Manjusha Gaglani, MBBS, Baylor
Scott & White Health, Texas A&M University College of Medicine; Anupam
B. Kharbanda, M.D., Children's Minnesota; Stephanie A. Irving, MHS,
Center for Health Research, Kaiser Permanente Northwest; Suchitra Rao,
MBBS, School of Medicine, University of Colorado Anschutz Medical
Campus; Shaun J. Grannis, M.D., Center for Biomedical Informatics,
Regenstrief Institute, Indiana University School of Medicine; Kristin
Dascomb, M.D., Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare; Kempapura Murthy, MBBS, Baylor Scott & White
Health; Elizabeth A.

Rowley, DrPH, Westat; Alexandra F. Dalton, PhD, Centers for Disease
Control and Prevention COVID-19 Response Team; Malini B. DeSilva, M.D., HealthPartners Institute; Brian E. Dixon, PhD, Center for Biomedical Informatics, Regenstrief Institute, Fairbanks School of Public Health,
Indiana University; Karthik Natarajan, PhD, New York-Presbyterian
Hospital, Department of Biomedical Informatics, Columbia University
Irving Medical Center; Edward Stenehjem, M.D., Division of Infectious
Diseases and Clinical Epidemiology, Intermountain Healthcare; Allison
L. Naleway, PhD, Center for Health Research, Kaiser Permanente Northwest;
Ned Lewis, MPH, Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research; Toan C. Ong, PhD, Children's Minnesota; Palak Patel, MBBS, Centers for Disease Control and Prevention COVID-19 Response Team; Deepika Konatham, Baylor Scott & White Health;
Peter J. Embi, M.D., Indiana University School of Medicine, Regenstrief Institute, Vanderbilt University Medical Center; Sarah E. Reese, PhD,
Westat; Jungmi Han, Department of Biomedical Informatics, Columbia
University Irving Medical Center; Nancy Grisel, MPP, Division of
Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare; Kristin Goddard, MPH, Kaiser Permanente Vaccine Study Center, Kaiser
Permanente Northern California Division of Research; Michelle A. Barron,
M.D., School of Medicine, University of Colorado Anschutz Medical Campus; Monica Dickerson, Centers for Disease Control and Prevention COVID-19
Response Team; I-Chia Liao, MPH, Baylor Scott & White Health; William
F. Fadel, PhD, Center for Biomedical Informatics, Regenstrief Institute, Fairbanks School of Public Health, Indiana University; Duck-Hye Yang,
PhD, Westat; Julie Arndorfer, MPH, Division of Infectious Diseases and
Clinical Epidemiology, Intermountain Healthcare; Bruce Fireman, Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California
Division of Research; Eric P. Griggs, MPH, Centers for Disease Control
and Prevention COVID-19 Response Team; Nimish R. Valvi, DrPH, Center
for Biomedical Informatics, Regenstrief Institute; Carly Hallowell,
MPH, Westat; Ousseny Zerbo, PhD, Kaiser Permanente Vaccine Study Center,
Kaiser Permanente Northern California Division of Research; Sue Reynolds,
PhD, Centers for Disease Control and Prevention COVID-19 Response Team;
Jill Ferdinands, PhD, Centers for Disease Control and Prevention COVID-19 Response Team; Mehiret H. Wondimu, MPH, Centers for Disease Control
and Prevention COVID-19 Response Team; Jeremiah Williams, MPH, Centers
for Disease Control and Prevention COVID-19 Response Team; Catherine
H. Bozio, PhD, Centers for Disease Control and Prevention COVID-19
Response Team; Ruth Link-Gelles, PhD, Centers for Disease Control and Prevention COVID-19 Response Team; Eduardo Azziz-Baumgartner, M.D.,
Centers for Disease Control and Prevention COVID-19 Response Team;
Stephanie J. Schrag, DPhil, Centers for Disease Control and Prevention
COVID-19 Response Team; Mark G. Thompson, PhD, Centers for Disease
Control and Prevention COVID-19 Response Team; Jennifer R. Verani, M.D., Centers for Disease Control and Prevention COVID-19 Response Team.

========================================================================== Story Source: Materials provided by Regenstrief_Institute. Note: Content
may be edited for style and length.


========================================================================== Journal Reference:
1. Nicola P. Klein, Melissa S. Stockwell, Maria Demarco, Manjusha
Gaglani,
Anupam B. Kharbanda, Stephanie A. Irving, Suchitra Rao, Shaun
J. Grannis, Kristin Dascomb, Kempapura Murthy, Elizabeth A. Rowley,
Alexandra F.

Dalton, Malini B. DeSilva, Brian E. Dixon, Karthik Natarajan, Edward
Stenehjem, Allison L. Naleway, Ned Lewis, Toan C. Ong, Palak Patel,
Deepika Konatham, Peter J. Embi, Sarah E. Reese, Jungmi Han, Nancy
Grisel, Kristin Goddard, Michelle A. Barron, Monica Dickerson,
I-Chia Liao, William F. Fadel, Duck-Hye Yang, Julie Arndorfer,
Bruce Fireman, Eric P. Griggs, Nimish R. Valvi, Carly Hallowell,
Ousseny Zerbo, Sue Reynolds, Jill Ferdinands, Mehiret H. Wondimu,
Jeremiah Williams, Catherine H. Bozio, Ruth Link-Gelles, Eduardo
Azziz-Baumgartner, Stephanie J. Schrag, Mark G. Thompson, Jennifer
R. Verani. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2
mRNA Vaccination in Preventing COVID-19-Associated Emergency
Department and Urgent Care Encounters and Hospitalizations Among
Nonimmunocompromised Children and Adolescents Aged 5-17 Years
&#82. MMWR. Morbidity and Mortality Weekly Report, 2022; 71 (9)
DOI: 10.15585/mmwr.mm7109e3 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2022/03/220301141243.htm

--- up 1 day, 10 hours, 50 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)